rs1060502839
Variant summary
Our verdict is Uncertain significance. Variant got 5 ACMG points: 5P and 0B. PM2PP3PP5_Moderate
The NM_002047.4(GARS1):c.1705G>A(p.Glu569Lys) variant causes a missense change involving the alteration of a conserved nucleotide. The variant was absent in control chromosomes in GnomAD project. In-silico tool predicts a pathogenic outcome for this variant. Variant has been reported in ClinVar as Likely pathogenic (★).
Frequency
Consequence
NM_002047.4 missense
Scores
Clinical Significance
Conservation
Genome browser will be placed here
ACMG classification
Verdict is Uncertain_significance. Variant got 5 ACMG points.
Transcripts
RefSeq
Ensembl
Gene | Transcript | HGVSc | HGVSp | Effect | Exon rank | TSL | MANE | Protein | Appris | UniProt |
---|---|---|---|---|---|---|---|---|---|---|
GARS1 | ENST00000389266.8 | c.1705G>A | p.Glu569Lys | missense_variant | Exon 14 of 17 | 1 | NM_002047.4 | ENSP00000373918.3 | ||
GARS1 | ENST00000675651.1 | c.1705G>A | p.Glu569Lys | missense_variant | Exon 14 of 17 | ENSP00000502513.1 | ||||
GARS1 | ENST00000675810.1 | c.1603G>A | p.Glu535Lys | missense_variant | Exon 13 of 16 | ENSP00000502743.1 | ||||
GARS1 | ENST00000675693.1 | c.1537G>A | p.Glu513Lys | missense_variant | Exon 15 of 18 | ENSP00000502174.1 | ||||
GARS1 | ENST00000675051.1 | c.1504G>A | p.Glu502Lys | missense_variant | Exon 14 of 17 | ENSP00000502296.1 | ||||
GARS1 | ENST00000674815.1 | c.1336G>A | p.Glu446Lys | missense_variant | Exon 14 of 17 | ENSP00000502799.1 | ||||
GARS1 | ENST00000674851.1 | c.1336G>A | p.Glu446Lys | missense_variant | Exon 15 of 18 | ENSP00000502451.1 | ||||
GARS1 | ENST00000444666.6 | n.*126G>A | non_coding_transcript_exon_variant | Exon 15 of 18 | 3 | ENSP00000415447.2 | ||||
GARS1 | ENST00000674616.1 | n.*1419G>A | non_coding_transcript_exon_variant | Exon 15 of 18 | ENSP00000502408.1 | |||||
GARS1 | ENST00000674643.1 | n.*805G>A | non_coding_transcript_exon_variant | Exon 15 of 17 | ENSP00000501636.1 | |||||
GARS1 | ENST00000674737.1 | n.*1043G>A | non_coding_transcript_exon_variant | Exon 15 of 18 | ENSP00000502464.1 | |||||
GARS1 | ENST00000674807.1 | n.1619G>A | non_coding_transcript_exon_variant | Exon 13 of 16 | ENSP00000502814.1 | |||||
GARS1 | ENST00000675529.1 | n.*1575G>A | non_coding_transcript_exon_variant | Exon 15 of 18 | ENSP00000501655.1 | |||||
GARS1 | ENST00000675859.1 | n.1619G>A | non_coding_transcript_exon_variant | Exon 13 of 15 | ENSP00000502033.1 | |||||
GARS1 | ENST00000676088.1 | n.*1647G>A | non_coding_transcript_exon_variant | Exon 16 of 19 | ENSP00000501884.1 | |||||
GARS1 | ENST00000676140.1 | n.*650G>A | non_coding_transcript_exon_variant | Exon 14 of 17 | ENSP00000502571.1 | |||||
GARS1 | ENST00000676164.1 | n.*1156G>A | non_coding_transcript_exon_variant | Exon 14 of 17 | ENSP00000501986.1 | |||||
GARS1 | ENST00000676210.1 | n.*994G>A | non_coding_transcript_exon_variant | Exon 15 of 18 | ENSP00000502373.1 | |||||
GARS1 | ENST00000676259.1 | n.*1137G>A | non_coding_transcript_exon_variant | Exon 14 of 17 | ENSP00000501980.1 | |||||
GARS1 | ENST00000676403.1 | n.1705G>A | non_coding_transcript_exon_variant | Exon 14 of 16 | ENSP00000502681.1 | |||||
GARS1 | ENST00000444666.6 | n.*126G>A | 3_prime_UTR_variant | Exon 15 of 18 | 3 | ENSP00000415447.2 | ||||
GARS1 | ENST00000674616.1 | n.*1419G>A | 3_prime_UTR_variant | Exon 15 of 18 | ENSP00000502408.1 | |||||
GARS1 | ENST00000674643.1 | n.*805G>A | 3_prime_UTR_variant | Exon 15 of 17 | ENSP00000501636.1 | |||||
GARS1 | ENST00000674737.1 | n.*1043G>A | 3_prime_UTR_variant | Exon 15 of 18 | ENSP00000502464.1 | |||||
GARS1 | ENST00000675529.1 | n.*1575G>A | 3_prime_UTR_variant | Exon 15 of 18 | ENSP00000501655.1 | |||||
GARS1 | ENST00000676088.1 | n.*1647G>A | 3_prime_UTR_variant | Exon 16 of 19 | ENSP00000501884.1 | |||||
GARS1 | ENST00000676140.1 | n.*650G>A | 3_prime_UTR_variant | Exon 14 of 17 | ENSP00000502571.1 | |||||
GARS1 | ENST00000676164.1 | n.*1156G>A | 3_prime_UTR_variant | Exon 14 of 17 | ENSP00000501986.1 | |||||
GARS1 | ENST00000676210.1 | n.*994G>A | 3_prime_UTR_variant | Exon 15 of 18 | ENSP00000502373.1 | |||||
GARS1 | ENST00000676259.1 | n.*1137G>A | 3_prime_UTR_variant | Exon 14 of 17 | ENSP00000501980.1 |
Frequencies
GnomAD3 genomes Cov.: 32
GnomAD4 exome Cov.: 29
GnomAD4 genome Cov.: 32
ClinVar
Submissions by phenotype
Charcot-Marie-Tooth disease type 2 Pathogenic:1
This sequence change replaces glutamic acid with lysine at codon 569 of the GARS protein (p.Glu569Lys). The glutamic acid residue is highly conserved and there is a small physicochemical difference between glutamic acid and lysine. This variant is not present in population databases (ExAC no frequency) and has not been reported in the literature in individuals with a GARS-related disease. Family studies have indicated that this variant was not present in the parents of an individual affected with distal spinal muscular atrophy, which suggests that it was de novo in that affected individual (Invitae). Algorithms developed to predict the effect of missense changes on protein structure and function (SIFT, PolyPhen-2, Align-GVGD) all suggest that this variant is likely to be disruptive, but these predictions have not been confirmed by published functional studies. In summary, this variant is a novel missense change that has been shown to arise de novo in an affected individual. This evidence indicates that the variant is pathogenic, but additional data is needed to prove that conclusively. Therefore, this variant has been classified as Likely Pathogenic. -
Computational scores
Source:
Splicing
Find out detailed SpliceAI scores and Pangolin per-transcript scores at